Unlike chemotherapy or radiation, which attack cancer directly, CAR-T engineers patients’ immune cells so they can do it themselves. T-cells are removed from the blood and given new genes that produce receptors that let the T-cells recognize and bind to leukemia cells with a specific protein, CD19.
The genetically modified T-cells are then multiplied in the lab and infused back into the patient, where they ideally multiply even further and begin to target and kill cancer cells with CD19.
Comments are closed.